WallStreetZenWallStreetZen

NASDAQ: CUE
Cue Biopharma Inc Stock Forecast, Predictions & Price Target

Analyst price target for CUE

Based on 2 analysts offering 12 month price targets for Cue Biopharma Inc.
Min Forecast
$6.00+217.46%
Avg Forecast
$7.00+270.37%
Max Forecast
$8.00+323.28%

Should I buy or sell CUE stock?

Based on 2 analysts offering ratings for Cue Biopharma Inc.
Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CUE stock forecasts and price targets.

CUE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-13
lockedlocked$00.00+00.00%2023-11-06

1 of 1

Forecast return on equity

Is CUE forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
37.27%

Forecast return on assets

Is CUE forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

CUE revenue forecast

What is CUE's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$9.0M+63.61%
Avg 2 year Forecast
$14.9M+172%
Avg 3 year Forecast
$32.4M+489.8%
CUE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CUE revenue growth forecast

How is CUE forecast to perform vs Biotechnology companies and vs the US market?
Company
76.88%
Industry
39.22%
Market
10.52%
CUE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CUE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CUE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CUE$1.89$7.00+270.37%Strong Buy
PLX$1.26$10.00+693.65%Buy
CARM$2.27$10.50+362.56%Buy
BRNS$2.38$8.00+236.13%Buy
SPRO$1.72$7.00+306.98%Buy

Cue Biopharma Stock Forecast FAQ

Is Cue Biopharma Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CUE) stock is to Strong Buy CUE stock.

Out of 2 analysts, 2 (100%) are recommending CUE as a Strong Buy, 0 (0%) are recommending CUE as a Buy, 0 (0%) are recommending CUE as a Hold, 0 (0%) are recommending CUE as a Sell, and 0 (0%) are recommending CUE as a Strong Sell.

If you're new to stock investing, here's how to buy Cue Biopharma stock.

What is CUE's revenue growth forecast for 2024-2026?

(NASDAQ: CUE) Cue Biopharma's forecast annual revenue growth rate of 76.88% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.

Cue Biopharma's revenue in 2024 is $5,490,000.On average, 4 Wall Street analysts forecast CUE's revenue for 2024 to be $436,914,264, with the lowest CUE revenue forecast at $38,914,653, and the highest CUE revenue forecast at $1,319,693,163. On average, 3 Wall Street analysts forecast CUE's revenue for 2025 to be $726,390,638, with the lowest CUE revenue forecast at $38,914,653, and the highest CUE revenue forecast at $1,945,732,640.

In 2026, CUE is forecast to generate $1,575,070,572 in revenue, with the lowest revenue forecast at $194,573,264 and the highest revenue forecast at $4,256,290,150.

What is CUE's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CUE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is CUE's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CUE price target, the average CUE price target is $7.00, with the highest CUE stock price forecast at $8.00 and the lowest CUE stock price forecast at $6.00.

On average, Wall Street analysts predict that Cue Biopharma's share price could reach $7.00 by Mar 13, 2025. The average Cue Biopharma stock price prediction forecasts a potential upside of 270.37% from the current CUE share price of $1.89.

What is CUE's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CUE) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.